Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukaemia (CLL) and Rheumatoid Arthritis apart from Non-Hodgkin's Lymphoma (NHL) in India. With a view to make NHL treatment cost-effective, Mabtas is manufactured in the state of the art, Asia’s only EU GMP facility of Intas Biopharmaceuticals, Ahmedabad.
With the launch of this product, Intas now is the only company to have indigenously developed six biosimilars in the domestic market. The company is India's first and only biopharmaceutical companies to receive European Union - Good Manufacturing Practice (EU-GMP) certification for its microbial manufacturing facility and only company having product under-registration with EMA. Intas Biopharmaceuticals is already a leading manufacturer of Erythropoietin, G-CSF and peg G-CSF for India and have introduced world’s first biosimilar peg G-CSF. Mabtas marks the first monoclonal antibody (mAb) launch from Intas. With this product Intas joins the ranks of select few Indian companies to launch a mAb product in the domestic market.
The company is now the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), January, 2013). Intas is one of the leading players in chronic therapy in domestic market. Its portfolio extends to central nervous system (CNS), cardiovascular system (CVS), oncology, diabetes, gastroenterology, pain management, urology, nephrology, gynaecology, infertility and respiratory care. Intas also has its extensive presence in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, South Africa, Australia and New Zealand among others.